Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Millennium Pharmaceuticals, Inc.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Voluntary written consent
Male patients 18 years or older
Estimated life expectancy of 6 months or more
Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
Radiograph-documented metastatic disease
Progressive disease
Prior surgical castration or concurrent use of an agent for medical castration
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Received antiandrogen therapy within 4 weeks for flutamide and 6 weeks for all others prior to first dose of study drug
Received prior chemotherapy for prostate cancer
Current spinal cord compression, bilateral hydronephrosis or neck outlet obstruction
Symptoms that investigator deems related to prostate cancer
Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected
Uncontrolled cardiovascular condition
New York Heart Association Class (NYHA) Class III or IV
Uncontrolled hypertension despite medical therapy
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Unwilling or unable to comply with protocol
Major surgery or serious infection within 14 days of first dose of TAK-700
Life-threatening illness unrelated to cancer
Uncontrolled nausea, vomiting or diarrhea
Known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of TAK-700
You may not be if
Even if surgically sterilized, patients must Practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug, OR Abstain from heterosexual intercourse
Any use of opiates must be stable for at least 2 weeks prior to study entry
Meet screening laboratory values as specified in protocol
Suitable venous access
Known hypersensitivity to TAK-700, docetaxel, prednisone or related compounds
Received any of the following within 30 days prior to the first dose of TAK-700: prior therapy with any investigational compound; prior herbal product known to decrease PSA; OR radiation therapy for prostate cancer
